Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

× No keyword cloud information.

22 in total

1. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors: A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal: Leukemia Date: 2014-11-14 Impact factor: 11.528

Review 2. Evolution of acquired resistance to anti-cancer therapy.

Authors: Jasmine Foo; Franziska Michor
Journal: J Theor Biol Date: 2014-03-25 Impact factor: 2.691

3. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Authors: Franck E Nicolini; Amr R Ibrahim; Simona Soverini; Giovanni Martinelli; Martin C Müller; Andreas Hochhaus; Inge H Dufva; Dong-Wook Kim; Jorge Cortes; Michael J Mauro; Charles Chuah; Hélène Labussière; Stéphane Morisset; Catherine Roche-Lestienne; Eric Lippert; Sandrine Hayette; Senaka Peter; Wei Zhou; Véronique Maguer-Satta; Mauricette Michallet; John Goldman; Jane F Apperley; François-Xavier Mahon; David Marin; Gabriel Etienne
Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941

4. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.

Authors: Hidehiro Itonaga; Hideki Tsushima; Tomoko Hata; Emi Matsuo; Daisuke Imanishi; Yoshitaka Imaizumi; Yasuhisa Kawaguchi; Takuya Fukushima; Yuko Doi; Sayaka Mori; Shimeru Kamihira; Masao Tomonaga; Yasushi Miyazaki
Journal: Int J Hematol Date: 2012-01-20 Impact factor: 2.490

5. How I treat childhood CML.

Authors: Jeffrey R Andolina; Steven M Neudorf; Seth J Corey
Journal: Blood Date: 2011-12-30 Impact factor: 22.113

6. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.

Authors: Filip Razga; Tomas Jurcek; Daniela Zackova; Dana Dvorakova; Martina Toskova; Ivana Jeziskova; Jiri Mayer; Zdenek Racil
Journal: Mol Diagn Ther Date: 2012-08-01 Impact factor: 4.074

7. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Authors: Franck E Nicolini; Michael J Mauro; Giovanni Martinelli; Dong-Wook Kim; Simona Soverini; Martin C Müller; Andreas Hochhaus; Jorge Cortes; Charles Chuah; Inge H Dufva; Jane F Apperley; Fumiharu Yagasaki; Jay D Pearson; Senaka Peter; Cesar Sanz Rodriguez; Claude Preudhomme; Francis Giles; John M Goldman; Wei Zhou
Journal: Blood Date: 2009-10-20 Impact factor: 22.113

8. Chronic myeloid leukemia: When the going gets tough.

Authors: Lucy A Pickard; Graham Knee; Vishal Jayakar
Journal: South Asian J Cancer Date: 2014-01

Review 9. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544

10. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

Authors: Yun Dai; Shuang Chen; Charis A Venditti; Xin-Yan Pei; Tri K Nguyen; Paul Dent; Steven Grant
Journal: Blood Date: 2008-05-27 Impact factor: 22.113